Detail akcie Quanterix Rg online

Business Summary: Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Quanterix Corp revenues increased 1% to $138.9M. Net loss increased from $38.5M to $107.2M. Revenues reflect Product revenue segment increase of 17% to $92.9M. Higher net loss reflects Selling, General & Administrative Expens increase of 22% to $104.9M (expense), Impairment and restructuring increase from $0K to $8M (expense).